PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

NCT05759546 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Metastatic

Interventions

DRUG: Fluzoparib
DRUG: Dalpiciclib
DRUG: Fulvestrant/AI

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]